Effects of sitagliptin beyond glycemic control: Focus on quality of life

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Sakamoto, Yoshiko ^a   Oyama, Jun ichi ^a   Ikeda, Hideo ^b   Kuroki, Shigetaka ^b   Gondo, Shigeki ^b   Iwamoto, Taketo ^b   Uchida, Yasufumi ^b   Kodama, Kazuhisa ^a   Hiwatashi, Atsushi ^a   Shimomura, Mitsuhiro ^a   Taguchi, Isao ^c   Inoue, Teruo ^c   Node, Koichi ^a   Gondoh, Shigeki ^d   Yoshio, Haruda ^d   Hashimoto, Minekazu ^d   Imamura, Takahiko ^d   Kaihara, Ryota ^d   Kamachi, Hideyuki ^d   Koga, Yoshiyuki ^d   Matsunaga, Kazuo ^d   Mizukami, Tadahiro ^d   Minami, Taizo ^d   Nakanishi, Hirosh ^d   Naito, Hirofumi ^d   Nakao, Masanori ^d   Nakayama, Masayuki ^d   Nakayama, Shinichi ^d   Takahashi, Akira ^d   Takeda, Norio ^d   Tajiri, Otohisa ^d   Tamesue, Satoshi ^d   Uchida, Toshifumi ^d   Wakiyama, Tetsushi ^d   Yamaguchi, Tsuneko ^d   Yamamoto, Kenichi ^d   more..

^a SAGA UNIVERSITY   (Japan)

^b Saga Medical Association   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d NONE

Author keywords

Blood pressure; Diabetes type 2; DPP 4 inhibitor; HbA1c; Metabolism

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; SITAGLIPTIN; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INTESTINE TUBERCULOSIS; JAPAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PEPTIC ULCER BLEEDING; PITTSBURGH SLEEP QUALITY INDEX; PNEUMONIA; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RASH; SIDE EFFECT; STOMACH PAIN; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINES; QUALITY OF LIFE; TREATMENT OUTCOME; TRIAZOLES;

EID: 84874012409     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-35     Document Type: Article

References (30)

1. Ministry of Health Labour and Welfare of Japan, report of health and nourishment in 2007 2007, Japan, Ministry of Health.
2. Gallwitz B. Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vasc Health Risk Manag 2007, 3:203-210. 10.2147/vhrm.2007.3.2.203, 1994027, 17580730.
3. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985, 28:704-707. 10.1007/BF00291980, 3905480.
4. de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008, 51:2263-2270. 10.1007/s00125-008-1149-y, 18795252.
5. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24. 10.1016/S0167-0115(99)00089-0, 10588446.
6. Brooks R. EuroQol: the current state of play. Health Policy 1996, 37:53-72. 10.1016/0168-8510(96)00822-6, 10158943.
7. Lamers L, McDonnell J, Stalmeier P, Krabbe PFM, Busschbach JJV. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006, 15:1121-1132. 10.1002/hec.1124, 16786549.
8. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108. 10.1097/00005650-199711000-00002, 9366889.
9. Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999, 3:1-164.
10. Parkin D, Rice N, Lacoby A, Doughty J. Use of a visual analogue scale in a daily patient diary: modelling cross-sectional time-series data on health-related quality of life. Soc Sci Med 2004, 54:351-360.
11. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 28:193-213. 10.1016/0165-1781(89)90047-4, 2748771.
12. Carpenter JS, Andrykowski A. Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosomatic Res 1998, 45:5-13.
13. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, . Sitagliptin Study 021 Group Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637. 10.2337/dc06-0703, 17130196, Sitagliptin Study 021 Group.
14. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008, 79:291-298. 10.1016/j.diabres.2007.08.021, 17933414.
15. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, . American Diabetes Association, European Association for Study of Diabetes Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203. 10.2337/dc08-9025, 2606813, 18945920, American Diabetes Association, European Association for Study of Diabetes.
16. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase C. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007, 30:389-394. 10.2337/dc06-1789, 17259518.
17. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007, 30:2148-2153. 10.2337/dc07-0141, 17536074.
18. Williams-Herman D, Round E, Swern AS, Musser B, Davies MJ, Stein PP, Kaufman KD, Amatruda JM. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders 2008, 8:14. 10.1186/1472-6823-8-14, 2605739, 18954434.
19. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013, 12:3. 10.1186/1475-2840-12-3, 3585887, 23286208.
20. Kishimoto M, Noda M. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc Diabetol 2011, 10:115. 10.1186/1475-2840-10-115, 3307032, 22189184.
21. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 2012, 11:92. 10.1186/1475-2840-11-92, 3471040, 22867630.
22. Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 1990, 265:8001-8008.
23. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and independent pathways. Circulation 2008, 117:2340-2350. 10.1161/CIRCULATIONAHA.107.739938, 18427132.
24. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004, 89:3055-3061. 10.1210/jc.2003-031403, 15181098.
25. Qin X, Shen H, Liu M, Yang Q, Zheng S, Sabo M, D'Alessio DA, Tso P. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005, 288:G943-G949. 10.1152/ajpgi.00303.2004, 15677555.
26. Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007, 56:3006-3013. 10.2337/db07-0697, 17717280.
27. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 1999, 354:1435-1439. 10.1016/S0140-6736(99)01376-8, 10543671.
28. Irwin M, Thompson J, Miller C, Gillin JC, Ziegler M. Effects of sleep and sleep deprivation on catecholamine and interleukin-2 levels in humans: clinical implications. J Clin Endocrinol Metab 1999, 84:1979-1985. 10.1210/jc.84.6.1979, 10372697.
29. Greene DA, Sima AA, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992, 15:1902-1925. 10.2337/diacare.15.12.1902, 1464245.
30. Clarke PM, Hayes AJ, Glasziou PG, Scott R, Simes J, Keech AC. Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Med Care 2009, 47:61-68. 10.1097/MLR.0b013e3181844855, 19106732.